Compare State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF (SJNK) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF vs Travere Therapeutics Inc. Common Stock — how do they compare? State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF trades at $24.09 (market cap $4.39B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF and Travere Therapeutics Inc. Common Stock are close in size by market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF for 42 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| SJNK | TVTX | |
|---|---|---|
Market Cap | $4.39B | $4.88B |
Volume | 1,736,904 | 1,668,577 |
Sector | Fixed Income | Health |
52-Week High | $25.57 | $67.52 |
52-Week Low | $24.10 | $26.79 |
Typical Hold Time | 42 Days | 0 Days |
Enterprise Value | — | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SJNK trades at $24.19, showing minimal daily movement with a slight decline of 0.21%. The technical outlook appears bearish based on moving averages, though oscillators suggest neutral conditions. Recent corporate actions include consistent dividend payments, with three distributions scheduled for late 2026 ranging from $0.14 to $0.15 per share. Institutional activity shows mixed sentiment with both position reductions and maintained stakes among major holders.
The ETF faces headwinds from bearish technical indicators while maintaining dividend distributions. Key risks include interest rate sensitivity and institutional selling pressure. The neutral oscillator reading suggests potential for stabilization, but the overall technical picture warrants caution for near-term positioning in this high-yield bond ETF.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF
SJNK invests in U.S. dollar-denominated high-yield corporate bonds with short-term maturities (under five years). It offers higher yields than investment-grade funds but with less interest rate sensitivity than longer-term junk bond ETFs.
Read more on SJNK →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
